These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 17699866)

  • 1. Suppression of Ewing's sarcoma tumor growth, tumor vessel formation, and vasculogenesis following anti vascular endothelial growth factor receptor-2 therapy.
    Zhou Z; Bolontrade MF; Reddy K; Duan X; Guan H; Yu L; Hicklin DJ; Kleinerman ES
    Clin Cancer Res; 2007 Aug; 13(16):4867-73. PubMed ID: 17699866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
    Zhou Z; Reddy K; Guan H; Kleinerman ES
    Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
    Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
    Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
    Dalal S; Berry AM; Cullinane CJ; Mangham DC; Grimer R; Lewis IJ; Johnston C; Laurence V; Burchill SA
    Clin Cancer Res; 2005 Mar; 11(6):2364-78. PubMed ID: 15788688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
    Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
    Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
    Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.
    Jia SF; Duan X; Worth LL; Guan H; Kleinerman ES
    Cancer Gene Ther; 2006 Oct; 13(10):948-57. PubMed ID: 16763609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance.
    Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D
    Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration.
    Morales-Arias J; Meyers PA; Bolontrade MF; Rodriguez N; Zhou Z; Reddy K; Chou AJ; Koshkina NV; Kleinerman ES
    Cancer; 2007 Oct; 110(7):1568-77. PubMed ID: 17694551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis.
    Shaheen RM; Tseng WW; Vellagas R; Liu W; Ahmad SA; Jung YD; Reinmuth N; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM
    Int J Oncol; 2001 Feb; 18(2):221-6. PubMed ID: 11172585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
    Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.
    Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K
    Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE; Beck AW; Shivakumar L; Shih J; Fleming JB; Brekken RA
    Ann Surg Oncol; 2006 Aug; 13(8):1145-55. PubMed ID: 16791450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM; Westwood G; Selby PJ; Lewis IJ; Burchill SA
    Cancer Res; 2000 Nov; 60(21):6160-70. PubMed ID: 11085540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow cells participate in tumor vessel formation that supports the growth of Ewing's sarcoma in the lung.
    Zhou Z; Stewart KS; Yu L; Kleinerman ES
    Angiogenesis; 2011 May; 14(2):125-33. PubMed ID: 21184173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of platelet endothelial cell adhesion molecule-1 in bone marrow cells in mice after skeletal unloading.
    Sakuma-Zenke M; Sakai A; Nakayamada S; Kunugita N; Tabata T; Uchida S; Tanaka S; Mori T; Nakai K; Tanaka Y; Nakamura T
    J Bone Miner Res; 2005 Jun; 20(6):1002-10. PubMed ID: 15883641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.